Benzinga | Nov 12, 2020 08:12AM EST

Alimera Sciences Highlights Clinical Data For ILUVIEN Will Be Presented At American Academy Of Ophthalmology Conference Nov. 13

Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN(r) will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020.

Posters include:

* Abstract # 30064808: "Outcomes from the prospective IDEAL registry study -- results achieved with the 0.2 ?g/day fluocinolone acetonide implant" -- Khoramnia, et. al.

* Abstract # 30064802: "Three-year real-world outcomes from the IRISS registry study, using the 0.2 ?g/day fluocinolone acetonide (FAc) implant" -- Khoramnia, et. al.

* Abstract # 30065140: "Predictive value IOP challenge and other safety measures of PALADIN 2yr. data" -- Malik, et. al.

"ILUVIEN is a uniquely durable therapy, providing physicians the opportunity to reduce the recurrence of diabetic macular edema, and therefore reduce the need for frequent injections of the current standard of care," said Rick Eiswirth, President and CEO of Alimera."We are very excited to have these abstracts showcased at the American Academy of Ophthalmology, highlighting the longer term three-year outcomes that support ILUVIEN's ability to give more DME patients the potential to see better, longer, with fewer injections."

Registration to the conference can be accessed here.